INO has been in the news 1200% more than usual
Dec 29, 2025, 7:31 PM
-1.13%
What does INO do
Inovio Pharmaceuticals, based in San Diego, develops DNA medicines targeting infectious diseases, cancer, and HPV-related conditions, with key candidates including INO-3107 for recurrent respiratory papillomatosis. The company employs 122 people and utilizes CELLECTRA devices for DNA delivery.
INO has been in the news recently: INOVIO Pharmaceuticals' Biologics License Application (BLA) for INO-3107, a treatment for recurrent respiratory papillomatosis (RRP), was accepted by the FDA, with a review goal date set for October 30, 2026. Despite this progress, INOVIO's stock experienced a decline due to concerns regarding the accelerated approval process, although the company reported a 15% increase in revenue this quarter, indicating strong market performance.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.